Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Antibody drug conjugates (ADC): Current status and mapping of ADC:s in clinical programs
Uppsala University, Disciplinary Domain of Science and Technology, Technology, Department of Engineering Sciences.
Uppsala University, Disciplinary Domain of Science and Technology, Technology, Department of Engineering Sciences.
Uppsala University, Disciplinary Domain of Science and Technology, Technology, Department of Engineering Sciences.
Uppsala University, Disciplinary Domain of Science and Technology, Technology, Department of Engineering Sciences.
2018 (English)Independent thesis Basic level (degree of Bachelor), 10 credits / 15 HE creditsStudent thesis
Abstract [en]

A literature study was performed on a new type of cancer medicine: antibody drug conjugates, or ADCs. These consist of a monoclonal antibody, chemically linked to a cytotoxic agent. What makes them unique is their selective toxicity against cancer cells. The first approval of such a pharmaceutical was in the year 2000, with three or four available in different regions of the world today. In the range of 50 registered drugs in clinical development were found, by major and minor corporations. These have been presented in a table in the appendix according to their properties such as type of linker, cytotoxin, development status etc. Furthermore, a detailed study has been done of the chemistry of the linker conjugation as well as an attempt at studying the ADC market. Finally, the mentioned strengths of the drug were compared to its weaknesses, mainly instability and otherwise poor pharmacokinetics. The main conclusion is that these drugs are expected to play a major role in oncology in the future.

Place, publisher, year, edition, pages
2018. , p. 42
Series
TVE-K ; TVE-K 18 005
Keywords [en]
ADC, antibody, drug, conjugate, biopharmaceuticals, structure, linker, payload, target, conjugation, market
National Category
Chemical Engineering
Identifiers
URN: urn:nbn:se:uu:diva-352917OAI: oai:DiVA.org:uu-352917DiVA, id: diva2:1215606
External cooperation
RISE AB
Educational program
Master Programme in Chemical Engineering
Supervisors
Examiners
Available from: 2018-06-19 Created: 2018-06-08 Last updated: 2018-06-19Bibliographically approved

Open Access in DiVA

fulltext(1727 kB)10 downloads
File information
File name FULLTEXT01.pdfFile size 1727 kBChecksum SHA-512
a55fc603a9d26c4e0b35fcfa9459223c187c3e61d609fe7a1480626c6b09540ded6ddbb45ccccff8eceff782f78596c93a3c6a6e57626d49e55040d7a68e688b
Type fulltextMimetype application/pdf
Antibody drug conjugates (ADC) Current status and mapping of ADC:s in clinical programs(1727 kB)28 downloads
File information
File name FULLTEXT02.pdfFile size 1727 kBChecksum SHA-512
1eb3714e86319624cc022e508947e696d18caa97e38314a620ffeedd0e2b7fe54d0d38d4aef721371674efd306185a86b608bd2a320db9115aca26e4409e8b2d
Type fulltextMimetype application/pdf

By organisation
Department of Engineering Sciences
Chemical Engineering

Search outside of DiVA

GoogleGoogle Scholar
Total: 38 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 4 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf